HK1162169A1 - 抗菌化合物 - Google Patents

抗菌化合物

Info

Publication number
HK1162169A1
HK1162169A1 HK12102532.7A HK12102532A HK1162169A1 HK 1162169 A1 HK1162169 A1 HK 1162169A1 HK 12102532 A HK12102532 A HK 12102532A HK 1162169 A1 HK1162169 A1 HK 1162169A1
Authority
HK
Hong Kong
Prior art keywords
antibacterial compounds
antibacterial
compounds
Prior art date
Application number
HK12102532.7A
Other languages
English (en)
Inventor
Francis Xavier Wilson
Peter David Johnson
Richard Vickers
Richard Storer
Graham Michael Wynne
Alan Geoffrey Roach
Moor Olivier De
Colin Richard Dorgan
Paul James Davis
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of HK1162169A1 publication Critical patent/HK1162169A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HK12102532.7A 2008-12-02 2012-03-13 抗菌化合物 HK1162169A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
PCT/GB2009/002792 WO2010063996A2 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Publications (1)

Publication Number Publication Date
HK1162169A1 true HK1162169A1 (zh) 2012-08-24

Family

ID=40262471

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12102532.7A HK1162169A1 (zh) 2008-12-02 2012-03-13 抗菌化合物
HK15109126.1A HK1208668A1 (zh) 2008-12-02 2015-09-17 抗菌藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15109126.1A HK1208668A1 (zh) 2008-12-02 2015-09-17 抗菌藥物組合物

Country Status (28)

Country Link
US (3) US8975416B2 (zh)
EP (3) EP3095783A1 (zh)
JP (3) JP5665756B2 (zh)
KR (1) KR101643435B1 (zh)
CN (1) CN102227411B (zh)
AU (1) AU2009323854B2 (zh)
BR (2) BR122020013025B1 (zh)
CA (1) CA2744962C (zh)
CY (2) CY1116383T1 (zh)
DK (2) DK2907813T3 (zh)
ES (2) ES2537059T3 (zh)
GB (1) GB0821913D0 (zh)
HK (2) HK1162169A1 (zh)
HR (2) HRP20150518T1 (zh)
HU (1) HUE029151T2 (zh)
IL (1) IL213325A (zh)
LT (1) LT2907813T (zh)
MX (1) MX2011005837A (zh)
NZ (1) NZ593111A (zh)
PL (2) PL2907813T3 (zh)
PT (2) PT2373631E (zh)
RS (1) RS54904B1 (zh)
RU (1) RU2525915C2 (zh)
SG (1) SG171939A1 (zh)
SI (2) SI2373631T1 (zh)
SM (2) SMT201500117B (zh)
WO (1) WO2010063996A2 (zh)
ZA (1) ZA201103751B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011151621A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
CN110917220A (zh) 2013-02-04 2020-03-27 赛里斯治疗公司 治疗组合物及其使用方法
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc MICROBIAL COMPOSITIONS AND ASSOCIATED METHODS BASED ON A NETWORK
CN116370507A (zh) 2013-11-25 2023-07-04 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
JP2020530840A (ja) 2017-08-14 2020-10-29 セレス セラピューティクス インコーポレイテッド 胆汁うっ滞性疾患を治療するための組成物及び方法
WO2019068383A1 (en) * 2017-10-05 2019-04-11 Sandoz Ag PROCESS FOR THE PREPARATION OF RIDINILAZOLE USING ACID ADDITION SALTS
WO2021009514A1 (en) 2019-07-17 2021-01-21 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
CN117529312A (zh) * 2021-05-24 2024-02-06 美商安满药物开发公司 治疗或预防细菌感染的普纳霉素ia和弗洛皮汀组合
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (zh) 1974-04-30 1975-11-11
JPS50154250A (zh) * 1974-05-31 1975-12-12
JPH03500661A (ja) 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
JPH09512831A (ja) 1994-11-17 1997-12-22 エフ・ホフマン−ラ ロシュ アーゲー ジベンズイミダゾール誘導体
CN1164227A (zh) 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
DE60107874T2 (de) 2000-11-27 2005-05-19 Ciba Speciality Chemicals Holding Inc. Substituierte 5-aryl- und 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazolderivate als uv-absorbierende substanzen
PT1341769E (pt) 2000-12-15 2007-12-31 Vertex Pharma Inibidores de girase bacteriana e suas utilizações
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003035065A1 (en) 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
DE60309701T2 (de) 2002-06-13 2007-09-06 Vertex Pharmaceuticals Inc., Cambridge 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
CA2496633A1 (en) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
AU2003291226B2 (en) 2002-11-01 2009-06-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
ZA200704476B (en) 2004-11-04 2008-09-25 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JP2008527032A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なチエノピロール
AU2006345003A1 (en) 2005-08-12 2008-04-10 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
AU2006311729A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
KR100744827B1 (ko) 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
US8536169B2 (en) 2008-06-05 2013-09-17 Glaxo Group Limited Compounds
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
BRPI1007836A2 (pt) 2009-02-27 2015-09-01 Enanta Phamaceuticals Inc Inibidores do vírus c da hepatite
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
NZ595674A (en) 2009-04-02 2012-12-21 Ct Nac Investigaciones Oncologicas Cnio Imidazo[2,1-b][1,3,4]thiadiazole derivatives
WO2010138575A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
EP2443123B1 (en) 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
CN102656141B (zh) 2009-10-13 2016-04-06 利亘制药公司 模拟造血生长因子的小分子化合物及其用途
WO2011151621A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease

Also Published As

Publication number Publication date
GB0821913D0 (en) 2009-01-07
PT2373631E (pt) 2015-06-09
CN102227411B (zh) 2015-10-14
HUE029151T2 (hu) 2017-02-28
US20120020950A1 (en) 2012-01-26
CY1116383T1 (el) 2017-02-08
IL213325A0 (en) 2011-07-31
PL2907813T3 (pl) 2016-09-30
US20160184283A1 (en) 2016-06-30
EP2907813B1 (en) 2016-04-27
CA2744962C (en) 2017-06-06
BRPI0922220B1 (pt) 2021-03-09
KR20110093925A (ko) 2011-08-18
KR101643435B1 (ko) 2016-07-27
SI2907813T1 (sl) 2016-09-30
SI2373631T1 (sl) 2015-08-31
HK1208668A1 (zh) 2016-03-11
CA2744962A1 (en) 2010-06-10
RU2011127165A (ru) 2013-01-10
NZ593111A (en) 2013-05-31
BR122020013025B1 (pt) 2021-05-18
SG171939A1 (en) 2011-07-28
BRPI0922220B8 (pt) 2021-05-25
ES2537059T3 (es) 2015-06-02
SMT201500117B (it) 2015-07-09
DK2907813T3 (en) 2016-07-25
MX2011005837A (es) 2011-11-18
RS54904B1 (sr) 2016-10-31
PT2907813T (pt) 2016-08-05
LT2907813T (lt) 2016-10-10
AU2009323854A2 (en) 2011-06-30
ZA201103751B (en) 2014-10-29
JP2017048217A (ja) 2017-03-09
BRPI0922220A8 (pt) 2018-04-03
CN102227411A (zh) 2011-10-26
JP2015078220A (ja) 2015-04-23
WO2010063996A3 (en) 2010-12-29
WO2010063996A2 (en) 2010-06-10
HRP20160597T1 (hr) 2016-09-23
US20150150861A1 (en) 2015-06-04
US9763925B2 (en) 2017-09-19
EP2907813A1 (en) 2015-08-19
AU2009323854A1 (en) 2010-06-10
PL2373631T3 (pl) 2015-10-30
IL213325A (en) 2016-02-29
SMT201600259B (it) 2016-08-31
DK2373631T3 (en) 2015-05-26
HRP20150518T1 (hr) 2015-07-17
ES2575908T3 (es) 2016-07-04
JP2012510458A (ja) 2012-05-10
CY1117934T1 (el) 2017-05-17
BRPI0922220A2 (pt) 2015-12-29
JP5665756B2 (ja) 2015-02-04
EP2373631A2 (en) 2011-10-12
RU2525915C2 (ru) 2014-08-20
EP3095783A1 (en) 2016-11-23
US8975416B2 (en) 2015-03-10
EP2373631B1 (en) 2015-02-25
US9314456B2 (en) 2016-04-19
AU2009323854B2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
HK1162169A1 (zh) 抗菌化合物
GB0807862D0 (en) Compounds
GB0800035D0 (en) Compounds
GB0815484D0 (en) Antibacterial agents
GB0804702D0 (en) Compounds
GB0807103D0 (en) Compounds
GB0800367D0 (en) Compounds
SI2321306T1 (sl) cianopirolidinil fenil oksazolidinoni kot antibakterijska sredstva
GB0807910D0 (en) Compounds
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0803060D0 (en) Novel antimicrobial compounds
GB0823284D0 (en) Novel antimicrobial compounds
GB0808119D0 (en) Compounds
GB0802587D0 (en) Compounds
GB0807047D0 (en) Compounds
GB0807911D0 (en) Compounds
GB0805815D0 (en) Compounds
GB0808123D0 (en) Compounds
GB0804064D0 (en) Compounds
GB0803496D0 (en) Compounds
GB0801219D0 (en) Compounds
GB0803495D0 (en) Compounds
GB0805048D0 (en) Niovel compounds
GB0800961D0 (en) Compounds